The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

Inclusion Criteria:

• Subjects must be diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian rube carcinoma)
• All subjects must be enrolled within 90 days of diagnosis
• No prior treatment for ovarian carcinoma
• All subjects have agreed to a treatment plan of neoadjuvant chemotherapy and subsequent planned interval debulking surgery with an MSKCC surgeon
• Participants must be initiating treatment at Gynecologic Medical Oncology clinics at MSKCC Manhattan
• Proficiency in English in the determination of the investigators of by patient self-report

Exclusion Criteria:

• Patient under age 18
• Prior treatment for ovarian cancer
• Second opinion visit only
• Immediate surgery plan without neoadjuvant treatment
• No intended surgical plan
• Chemotherapy administration exclusively planned at MSKCC regional site
• Patient unwilling to sign consent

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.